Biodesix Inc
Research Biodesix Inc (BDSX) on Bullrun: market cap USD 296.19M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBDSX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyUSD
- Market capUSD 296.19M
- Financial periodQ2 2026
- RevenueUSD 26.86M
- Net income-USD 7.27M
- Free cash flow-USD 1.82M
- Gross margin82.1%
Valuation Snapshot
latest market cap is USD 296.19M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 88.50M | -USD 35.27M | -USD 23.53M | 81.1% | -4.67 | USD 18.99M | USD 50.01M | -USD 2.47M |
| FY2024 | USD 71.32M | -USD 42.93M | -USD 51.88M | 78.2% | -6.64 | USD 26.25M | USD 40.03M | USD 20.88M |
| FY2023 | USD 49.09M | -USD 52.15M | -USD 45.79M | n/a | -0.64 | USD 26.28M | USD 40.08M | USD 4.58M |
| FY2022 | USD 38.21M | -USD 65.45M | -USD 48.27M | n/a | -1.55 | USD 43.09M | USD 30.13M | USD 20.61M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 296.19M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 54.10M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 222.60M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 166.48M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 175.94M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 162.88M | n/a | n/a | n/a |
About Biodesix Inc
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Biodesix Inc's market cap?
Biodesix Inc's market capitalization is USD 296.19M.
What does Biodesix Inc do?
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.